

Reinhard Dummer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3486836/publications.pdf>

Version: 2024-02-01

662
papers

83,961
citations

993

114
h-index

449

273
g-index

691
all docs

691
docs citations

691
times ranked

58593
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. <i>New England Journal of Medicine</i> , 2011, 364, 2507-2516.	13.9	6,976
2	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015, 373, 23-34.	13.9	6,773
3	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1345-1356.	13.9	3,589
4	Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells. <i>Nature Medicine</i> , 1998, 4, 328-332.	15.2	2,689
5	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 1535-1546.	13.9	2,484
6	Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. <i>Science</i> , 2015, 350, 207-211.	6.0	2,275
7	Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. <i>New England Journal of Medicine</i> , 2015, 372, 30-39.	13.9	2,240
8	Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. <i>New England Journal of Medicine</i> , 2012, 367, 107-114.	13.9	1,976
9	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 908-918.	5.1	1,419
10	COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. <i>Nature</i> , 2010, 468, 968-972.	13.7	1,325
11	Revisions to the staging and classification of mycosis fungoides and SÅ©zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). <i>Blood</i> , 2007, 110, 1713-1722.	0.6	1,243
12	Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1813-1823.	13.9	1,192
13	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. <i>New England Journal of Medicine</i> , 2016, 375, 1845-1855.	13.9	1,140
14	Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. <i>Cell</i> , 2017, 170, 1109-1119.e10.	13.5	1,124
15	Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC Tj ETQq1 1 0,784314 rgBT /Overall	5.1	1,093
16	Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1480-1492.	5.1	1,089
17	Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. <i>New England Journal of Medicine</i> , 2017, 376, 2211-2222.	13.9	1,087
18	High-throughput oncogene mutation profiling in human cancer. <i>Nature Genetics</i> , 2007, 39, 347-351.	9.4	927

#	ARTICLE	IF	CITATIONS
19	Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. <i>Lancet Oncology, The</i> , 2014, 15, 323-332.	5.1	890
20	The Genetic Evolution of Melanoma from Precursor Lesions. <i>New England Journal of Medicine</i> , 2015, 373, 1926-1936.	13.9	824
21	Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2018, 19, 603-615.	5.1	751
22	Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. <i>Nature</i> , 2013, 494, 251-255.	13.7	665
23	<i>In vivo</i> Switching of Human Melanoma Cells between Proliferative and Invasive States. <i>Cancer Research</i> , 2008, 68, 650-656.	0.4	631
24	Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. <i>Lancet, The</i> , 2008, 372, 117-126.	6.3	620
25	Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. <i>Lancet Oncology, The</i> , 2019, 20, 1083-1097.	5.1	611
26	MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. <i>Lancet Oncology, The</i> , 2013, 14, 249-256.	5.1	587
27	High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. <i>Nature Medicine</i> , 2018, 24, 144-153.	15.2	564
28	Clinical End Points and Response Criteria in Mycosis Fungoides and S�azary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2598-2607.	0.8	550
29	Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. <i>European Journal of Cancer</i> , 2016, 60, 190-209.	1.3	546
30	Toward Minimal Residual Disease-Directed Therapy in Melanoma. <i>Cell</i> , 2018, 174, 843-855.e19.	13.5	514
31	Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. <i>Cell</i> , 2015, 162, 1242-1256.	13.5	507
32	Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. <i>European Journal of Cancer</i> , 2016, 60, 210-225.	1.3	490
33	Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. <i>Pigment Cell & Melanoma Research</i> , 2006, 19, 290-302.	4.0	483
34	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2016, 22, 5487-5496.	3.2	480
35	Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018, 19, 1315-1327.	5.1	469
36	TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and S�azary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). <i>Blood</i> , 2007, 110, 479-484.	0.6	452

#	ARTICLE	IF	CITATIONS
37	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 127-137.	0.8	446
38	Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. <i>Lancet, The</i> , 2017, 390, 555-566.	6.3	444
39	European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. <i>Blood</i> , 2008, 112, 1600-1609.	0.6	415
40	The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network. <i>PLoS ONE</i> , 2013, 8, e53745.	1.1	414
41	Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. <i>Cancer Immunology Research</i> , 2017, 5, 417-424.	1.6	400
42	Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2017, 18, 435-445.	5.1	399
43	Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. <i>Lancet Oncology, The</i> , 2018, 19, 1192-1204.	5.1	398
44	Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2019, 30, 1884-1901.	0.6	394
45	EORTC consensus recommendations for the treatment of mycosis fungoides/SÅ©zary syndrome. <i>European Journal of Cancer</i> , 2006, 42, 1014-1030.	1.3	390
46	Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. <i>New England Journal of Medicine</i> , 2021, 385, 1196-1206.	13.9	376
47	EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma*. <i>Blood</i> , 2011, 118, 4024-4035.	0.6	365
48	Psoriasis Triggered by Toll-like Receptor 7 Agonist Imiquimod in the Presence of Dermal Plasmacytoid Dendritic Cell Precursors. <i>Archives of Dermatology</i> , 2004, 140, 1490-5.	1.7	364
49	European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/SÅ©zary syndrome â€” Update 2017. <i>European Journal of Cancer</i> , 2017, 77, 57-74.	1.3	363
50	Diagnosis and treatment of basal cell carcinoma: European consensusâ€”based interdisciplinary guidelines. <i>European Journal of Cancer</i> , 2019, 118, 10-34.	1.3	345
51	Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2012, 23, vii86-vii91.	0.6	336
52	Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. <i>Lancet Oncology, The</i> , 2015, 16, 716-728.	5.1	325
53	WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. <i>Journal of Cutaneous Pathology</i> , 2005, 32, 647-674.	0.7	313
54	Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2015, 26, v126-v132.	0.6	308

#	ARTICLE	IF	CITATIONS
55	Human CD271-Positive Melanoma Stem Cells Associated with Metastasis Establish Tumor Heterogeneity and Long-term Growth. <i>Cancer Research</i> , 2011, 71, 3098-3109.	0.4	294
56	The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. <i>Nature Communications</i> , 2015, 6, 6051.	5.8	281
57	Modeling Genomic Diversity and Tumor Dependency in Malignant Melanoma. <i>Cancer Research</i> , 2008, 68, 664-673.	0.4	275
58	Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 555-567.	3.2	267
59	Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. <i>New England Journal of Medicine</i> , 2020, 383, 1139-1148.	13.9	256
60	Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study. <i>European Journal of Cancer</i> , 2014, 50, 611-621.	1.3	254
61	Integrative analysis of the melanoma transcriptome. <i>Genome Research</i> , 2010, 20, 413-427.	2.4	248
62	Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2022, 399, 1718-1729.	6.3	236
63	Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma. <i>Nature Cell Biology</i> , 2012, 14, 882-890.	4.6	232
64	EANOâ€“ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. <i>Annals of Oncology</i> , 2021, 32, 1332-1347.	0.6	227
65	Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600â€“Mutant Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3441-3449.	0.8	226
66	Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective <i>BRAF</i> Inhibition. <i>Journal of Clinical Oncology</i> , 2012, 30, 2375-2383.	0.8	216
67	Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. <i>European Journal of Cancer</i> , 2017, 86, 334-348.	1.3	212
68	Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. <i>Cancer</i> , 2003, 98, 993-1001.	2.0	211
69	Aldara activates TLR7-independent immune defence. <i>Nature Communications</i> , 2013, 4, 1560.	5.8	211
70	A clinical study comparing methyl aminolevulinic acid photodynamic therapy and surgery in small superficial basal cell carcinoma (8â€“20Âmm), with a 12â€“month follow-up. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008, 22, 1302-1311.	1.3	208
71	Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. <i>Lancet Oncology, The</i> . 2015, 16, 1389-1398.	5.1	206
72	Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. <i>Nature Communications</i> , 2019, 10, 3163.	5.8	205

#	ARTICLE	IF	CITATIONS
73	Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. <i>Annals of Oncology</i> , 2017, 28, 2581-2587.	0.6	201
74	A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 1900-1909.	3.2	199
75	Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. <i>Lancet Oncology</i> , The, 2015, 16, 729-736.	5.1	198
76	Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. <i>Cancer Cell</i> , 2016, 29, 270-284.	7.7	198
77	Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.. <i>Journal of Clinical Oncology</i> , 1997, 15, 2579-2588.	0.8	192
78	Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032). <i>European Journal of Cancer</i> , 2011, 47, 1476-1483.	1.3	189
79	Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. <i>European Journal of Cancer</i> , 2017, 86, 37-45.	1.3	183
80	A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. <i>British Journal of Dermatology</i> , 2002, 146, 1042-1046.	1.4	173
81	Disease-Independent Skin Recruitment and Activation of Plasmacytoid Predendritic Cells Following Imiquimod Treatment. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1143-1153.	3.0	173
82	Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019, 106, 12-23.	1.3	171
83	Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. <i>Annals of Oncology</i> , 2019, 30, 1154-1161.	0.6	170
84	Sezary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain). <i>Blood</i> , 1996, 88, 1383-1389.	0.6	166
85	Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. <i>Blood</i> , 2005, 106, 2287-2294.	0.6	166
86	Predictors of responses to immune checkpoint blockade in advanced melanoma. <i>Nature Communications</i> , 2017, 8, 592.	5.8	166
87	Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 4023-4029.	3.2	160
88	Ultraviolet A and Photosensitivity during Vemurafenib Therapy. <i>New England Journal of Medicine</i> , 2012, 366, 480-481.	13.9	156
89	Interleukin-15 Is an Autocrine/Paracrine Viability Factor for Cutaneous T-Cell Lymphoma Cells. <i>Blood</i> , 1998, 92, 252-258.	0.6	155
90	Systematic classification of melanoma cells by phenotype-specific gene expression mapping. <i>Pigment Cell and Melanoma Research</i> , 2012, 25, 343-353.	1.5	155

#	ARTICLE	IF	CITATIONS
91	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	5.1	155
92	Metastatic basal cell carcinoma: Prognosis dependent on anatomic site and spread of disease. <i>European Journal of Cancer</i> , 2014, 50, 774-783.	1.3	154
93	HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. <i>Blood</i> , 2002, 99, 609-617.	0.6	152
94	Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. <i>Lancet Oncology</i> , The, 2013, 14, 733-740.	5.1	151
95	The optimal use of bexarotene in cutaneous T-cell lymphoma. <i>British Journal of Dermatology</i> , 2007, 157, 433-440.	1.4	150
96	Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 848-857.	5.1	150
97	Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 372-381.	1.3	144
98	Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma. <i>Clinical Cancer Research</i> , 2017, 23, 5339-5348.	3.2	142
99	Serological detection of cutaneous T-cell lymphoma-associated antigens. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 629-634.	3.3	139
100	Serum S100 – A Marker for Disease Monitoring in Metastatic Melanoma. <i>Dermatology</i> , 1997, 194, 208-212.	0.9	138
101	Intratumoral Injection of DNA Encoding Human Interleukin 12 into Patients with Metastatic Melanoma: Clinical Efficacy. <i>Human Gene Therapy</i> , 2005, 16, 35-48.	1.4	137
102	Complement Is a Central Mediator of Radiotherapy-Induced Tumor-Specific Immunity and Clinical Response. <i>Immunity</i> , 2015, 42, 767-777.	6.6	135
103	Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial. <i>Annals of Oncology</i> , 2017, 28, 1380-1387.	0.6	134
104	TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms. <i>Scientific Reports</i> , 2015, 5, 11200.	1.6	133
105	The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 113-125.e5.	0.6	133
106	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. <i>European Journal of Cancer</i> , 2019, 119, 1-10.	1.3	132
107	ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , 2020, 31, 1435-1448.	0.6	132
108	Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. <i>European Journal of Cancer</i> , 2020, 126, 33-44.	1.3	130

#	ARTICLE	IF	CITATIONS
109	Hypoxia Contributes to Melanoma Heterogeneity by Triggering HIF1 α -Dependent Phenotype Switching. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2436-2443.	0.3	127
110	The PROCLIFI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. <i>British Journal of Dermatology</i> , 2019, 181, 350-357.	1.4	127
111	Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. <i>Cancer</i> , 2000, 89, 1835-1844.	2.0	126
112	Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. <i>Blood</i> , 2003, 102, 2338-2344.	0.6	125
113	Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma. <i>Oncologist</i> , 2016, 21, 1218-1229.	1.9	125
114	Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial. <i>European Journal of Cancer</i> , 2013, 49, 386-394.	1.3	124
115	EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation. <i>Cancer Cell</i> , 2018, 34, 69-84.e14.	7.7	123
116	Pegylated liposomal doxorubicin-associated hand-foot syndrome: Recommendations of an international panel of experts. <i>European Journal of Cancer</i> , 2008, 44, 781-790.	1.3	122
117	Development of encorafenib for BRAF-mutated advanced melanoma. <i>Current Opinion in Oncology</i> , 2018, 30, 125-133.	1.1	122
118	Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). <i>European Journal of Cancer</i> , 2019, 114, 117-127.	1.3	120
119	The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe. <i>Current Oncology Reports</i> , 2018, 20, 87.	1.8	119
120	Biomarkers in melanoma. <i>Annals of Oncology</i> , 2009, 20, vi8-vi13.	0.6	118
121	Transient MEK inhibitor-associated retinopathy in metastatic melanoma. <i>Annals of Oncology</i> , 2014, 25, 1437-1441.	0.6	117
122	Superficial radiotherapy for patients with basal cell carcinoma. <i>Cancer</i> , 2003, 98, 2708-2714.	2.0	114
123	Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5 $\alpha^{-/-}$ mice. <i>Nature Communications</i> , 2019, 10, 1492.	5.8	114
124	Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma. <i>Cancer Immunology Research</i> , 2019, 7, 77-85.	1.6	114
125	Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. <i>Oncolmmunology</i> , 2016, 5, e1238557.	2.1	113
126	Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. <i>British Journal of Cancer</i> , 2017, 116, 1141-1147.	2.9	112

#	ARTICLE	IF	CITATIONS
127	Temozolomide in Combination With Interferon-Alfa Versus Temozolomide Alone in Patients With Advanced Metastatic Melanoma: A Randomized, Phase III, Multicenter Study from the Dermatologic Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 9001-9007.	0.8	111
128	Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myc genes in cutaneous T-cell lymphoma cells. <i>Blood</i> , 2001, 98, 2778-2783.	0.6	109
129	Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. <i>British Journal of Dermatology</i> , 2006, 155, 261-266.	1.4	108
130	Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 108-108.	0.8	107
131	Tyrosinase immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. <i>Journal of Cutaneous Pathology</i> , 1998, 25, 204-209.	0.7	104
132	Adenovirus-mediated intralesional interferon- β gene transfer induces tumor regressions in cutaneous lymphomas. <i>Blood</i> , 2004, 104, 1631-1638.	0.6	104
133	Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. <i>British Journal of Dermatology</i> , 2020, 182, 1369-1378.	1.4	104
134	An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2008, 14, 856-864.	3.2	103
135	Hedgehog Pathway Inhibitors Promote Adaptive Immune Responses in Basal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 1289-1297.	3.2	101
136	Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophages. <i>Scientific Reports</i> , 2016, 6, 29914.	1.6	99
137	Prospective International Multicenter Phase II Trial of Intravenous Pegylated Liposomal Doxorubicin Monochemotherapy in Patients With Stage IIB, IVA, or IVB Advanced Mycosis Fungoides: Final Results From EORTC 21012. <i>Journal of Clinical Oncology</i> , 2012, 30, 4091-4097.	0.8	94
138	Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1944-1956.	1.3	94
139	Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 358-372.	5.1	94
140	HLA-G and IL-10 expression in human cancer—different stories with the same message. <i>Seminars in Cancer Biology</i> , 2003, 13, 337-342.	4.3	91
141	Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 393-403.	5.1	91
142	Updated Swiss Guidelines for the Treatment and Follow-Up of Cutaneous Melanoma. <i>Dermatology</i> , 2005, 210, 39-44.	0.9	90
143	Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600E-Mutant Unresectable or Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1428-1438.	0.8	90
144	Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF ^{V600E} -mutated melanoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8502-8502.	0.8	86

#	ARTICLE	IF	CITATIONS
145	Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid. Archives of Dermatological Research, 1996, 288, 353-357.	1.1	85
146	Antagonistic Cross-Regulation between Sox9 and Sox10 Controls an Anti-tumorigenic Program in Melanoma. PLoS Genetics, 2015, 11, e1004877.	1.5	85
147	Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2010, 21, v194-v197.	0.6	83
148	Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching. Pigment Cell and Melanoma Research, 2011, 24, 631-642.	1.5	81
149	Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity. European Journal of Cancer, 2016, 55, 111-121.	1.3	80
150	Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-I. Nature Medicine, 2020, 26, 1557-1563.	15.2	78
151	Randomized Dose-Escalation Study Evaluating Peginterferon Alfa-2a in Patients With Metastatic Malignant Melanoma. Journal of Clinical Oncology, 2006, 24, 1188-1194.	0.8	77
152	Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. European Journal of Cancer, 2016, 67, 46-54.	1.3	77
153	The state of melanoma: challenges and opportunities. Pigment Cell and Melanoma Research, 2016, 29, 404-416.	1.5	77
154	Primary cutaneous B-cell lymphomas – Clinicopathological, prognostic and therapeutic characterisation of 54 cases according to the WHO-EORTC classification and the ISCL/EORTC TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and S�azary syndrome. Leukemia and Lymphoma, 2008, 49, 1094-1103.	0.6	76
155	Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma. Genome Biology, 2015, 16, 42.	3.8	76
156	Health-related quality of life results from the phase III CheckMate 067 study. European Journal of Cancer, 2017, 82, 80-91.	1.3	76
157	Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology. Journal of Dermatological Treatment, 2017, 28, 431-442.	1.1	76
158	Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.. Journal of Clinical Oncology, 2016, 34, 9568-9568.	0.8	76
159	Pseudo-Melanoma after Laser Therapy. Dermatology, 1998, 197, 71-73.	0.9	75
160	Imiquimod in basal cell carcinoma: how does it work?. British Journal of Dermatology, 2003, 149, 57-58.	1.4	75
161	Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. European Journal of Cancer, 2019, 119, 97-106.	1.3	75
162	Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution. Melanoma Research, 1998, 8, 337-343.	0.6	74

#	ARTICLE	IF	CITATIONS
163	Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma		

#	ARTICLE	IF	CITATIONS
181	The low affinity neurotrophin receptor CD271 regulates phenotype switching in melanoma. <i>Nature Communications</i> , 2017, 8, 1988.	5.8	64
182	Constitutive and Interleukin-7- and Interleukin-15-Stimulated DNA Binding of STAT and Novel Factors in Cutaneous T Cell Lymphoma Cells. <i>Journal of Investigative Dermatology</i> , 2001, 117, 583-589.	0.3	63
183	Junctional CD8+ Cutaneous Lymphomas With Nonaggressive Clinical Behavior. <i>Archives of Dermatology</i> , 2002, 138, 199-203.	1.7	63
184	Intra-lesional low-dose interferon β 2a therapy for primary cutaneous marginal zone B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 865-869.	0.6	63
185	Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. <i>EMBO Molecular Medicine</i> , 2017, 9, 1011-1029.	3.3	63
186	Electrical Impedance Spectroscopy in Skin Cancer Diagnosis. <i>Dermatologic Clinics</i> , 2017, 35, 489-493.	1.0	63
187	Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600E/K mutant advanced or metastatic melanoma. <i>European Journal of Cancer</i> , 2019, 109, 61-69.	1.3	63
188	Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective. <i>Cancer Cell</i> , 2021, 39, 394-406.e4.	7.7	63
189	Serological detection of cutaneous T-cell lymphoma-associated antigens. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 629-34.	3.3	63
190	Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibition Results in Biphasic Alteration of Epidermal Homeostasis with Keratinocytic Apoptosis and Pigmentation Disorders. <i>Clinical Cancer Research</i> , 2010, 16, 1058-1064.	3.2	62
191	<i>In Vivo</i> E2F Reporting Reveals Efficacious Schedules of MEK1/2/CDK4/6 Targeting and mTOR/S6 Resistance Mechanisms. <i>Cancer Discovery</i> , 2018, 8, 568-581.	7.7	62
192	Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy†. <i>Annals of Oncology</i> , 2020, 31, 1075-1082.	0.6	62
193	Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy. <i>European Journal of Cancer</i> , 2021, 157, 214-224.	1.3	62
194	CD4CD56 hematodermic neoplasms bear a plasmacytoid dendritic cell phenotype. <i>Human Pathology</i> , 2005, 36, 1020-1024.	1.1	61
195	Higher Frequency of Selective Losses of HLA-A and -B Allospecificities in Metastasis Than in Primary Melanoma Lesions. <i>Journal of Investigative Dermatology</i> , 1998, 111, 497-502.	0.3	60
196	A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status. <i>Pigment Cell and Melanoma Research</i> , 2011, 24, 326-333.	1.5	60
197	Blastic natural killer-cell lymphoma of the skin associated with myelodysplastic syndrome or myelogenous leukaemia: a coincidence or more?. <i>British Journal of Dermatology</i> , 2003, 149, 869-876.	1.4	59
198	Evolving impact of long-term survival results on metastatic melanoma treatment. , 2020, 8, e000948.		59

#	ARTICLE	IF	CITATIONS
199	Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage III/IV melanoma: a randomized, open-label, phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 1789-1796.	15.2	59
200	Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: <i>in vitro</i> and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition. <i>Leukemia and Lymphoma</i> , 2012, 53, 1501-1508.	0.6	58
201	MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients. <i>European Journal of Cancer</i> , 2018, 98, 10-16.	1.3	57
202	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. <i>European Journal of Cancer</i> , 2021, 144, 182-191.	1.3	57
203	Maintenance therapy in cutaneous T-cell lymphoma: Who, when, what?. <i>European Journal of Cancer</i> , 2007, 43, 2321-2329.	1.3	56
204	3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. <i>European Journal of Cancer</i> , 2015, 51, S663.	1.3	56
205	LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600E mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial. <i>Annals of Oncology</i> , 2020, 31, S1172.	0.6	56
206	Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. <i>Lancet Oncology</i> , The, 2014, 15, 297-304.	5.1	55
207	Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation. <i>Cell Reports</i> , 2015, 11, 1458-1473.	2.9	55
208	Hedgehog signaling in basal cell carcinoma. <i>Journal of Dermatological Science</i> , 2015, 78, 95-100.	1.0	55
209	MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects. <i>European Journal of Cancer</i> , 2016, 65, 130-138.	1.3	55
210	Peripheral Blood Mononuclear Cells in Patients With Nonleukemic Cutaneous T-Cell Lymphoma. <i>Archives of Dermatology</i> , 1993, 129, 433.	1.7	53
211	Resistance patterns with tyrosine kinase inhibitors in melanoma. <i>Current Opinion in Oncology</i> , 2012, 24, 150-154.	1.1	53
212	Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 683-695.	2.0	53
213	Tumor Cell Plasticity and Angiogenesis in Human Melanomas. <i>PLoS ONE</i> , 2012, 7, e33571.	1.1	53
214	Green tea extract reduces induction of p53 and apoptosis in UVB irradiated human skin independent of transcriptional controls. <i>Experimental Dermatology</i> , 2009, 18, 69-77.	1.4	52
215	Brentuximab as a Treatment for CD30 ⁺ Mycosis Fungoides and S�azary Syndrome. <i>JAMA Dermatology</i> , 2015, 151, 73.	2.0	52
216	Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9502-9502.	0.8	52

#	ARTICLE	IF	CITATIONS
217	Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL. <i>Clinical Cancer Research</i> , 2016, 22, 2020-2031.	3.2	51
218	The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients. <i>European Journal of Cancer</i> , 2017, 86, 101-105.	1.3	51
219	The influence of sentinel lymph node tumour burden on additional lymph node involvement and disease-free survival in cutaneous melanoma – a retrospective analysis of 392 cases. <i>British Journal of Cancer</i> , 2008, 98, 1922-1928.	2.9	50
220	Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 701-710.	5.1	50
221	Constitutive and Interleukin-7/Interleukin-15 Stimulated DNA Binding of Myc, Jun, and Novel Myc-Like Proteins in Cutaneous T-Cell Lymphoma Cells. <i>Blood</i> , 1999, 93, 260-267.	0.6	49
222	Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors. <i>Cancer Gene Therapy</i> , 2000, 7, 1069-1076.	2.2	49
223	Regulatory T Cells Restrain Pathogenic T Helper Cells during Skin Inflammation. <i>Cell Reports</i> , 2018, 25, 3564-3572.e4.	2.9	49
224	Cytokine Release Syndrome During Sequential Treatment With Immune Checkpoint Inhibitors and Kinase Inhibitors for Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2019, 42, 29-32.	1.2	49
225	Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions. <i>Experimental Dermatology</i> , 2011, 20, 685-688.	1.4	48
226	Sorafenib in melanoma. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 557-568.	1.9	48
227	Peripheral blood mononuclear cells in patients with nonleukemic cutaneous T-cell lymphoma. Reduced proliferation and preferential secretion of a T helper-2-like cytokine pattern on stimulation. <i>Archives of Dermatology</i> , 1993, 129, 433-436.	1.7	48
228	Non-self-discrimination as a driving concept in the identification of an immunodominant HMW-MAA epitopic peptide sequence by autoantibodies from melanoma cancer patients. <i>International Journal of Cancer</i> , 2004, 111, 720-726.	2.3	47
229	Cutaneous malignant melanoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2009, 20, iv129-iv131.	0.6	47
230	Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. <i>Annals of Oncology</i> , 2014, 25, 700-706.	0.6	47
231	Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma. <i>JAMA Oncology</i> , 2020, 6, 1957.	3.4	46
232	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. , 2021, 9, e001931.		46
233	Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling. <i>Nature Communications</i> , 2021, 12, 1434.	5.8	46
234	Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. <i>Blood Advances</i> , 2021, 5, 5098-5106.	2.5	46

#	ARTICLE	IF	CITATIONS
235	Genotypic, phenotypic and functional analysis of CD4 + CD7 + and CD4 + CD7 - T lymphocyte subsets in SÅ©zary syndrome. Archives of Dermatological Research, 1999, 291, 307-311.	1.1	45
236	Developments in targeted therapy in melanoma. European Journal of Surgical Oncology, 2017, 43, 581-593.	0.5	45
237	Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K mutant cutaneous melanoma. Annals of Oncology, 2016, 27, vi575.	0.6	44
238	Yin Yang 1 Orchestrates a Metabolic Program Required for Both Neural Crest Development and Melanoma Formation. Cell Stem Cell, 2019, 24, 637-653.e9.	5.2	44
239	Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. , 2019, 7, 50.		44
240	Senescent fibroblast-derived Chemerin promotes squamous cell carcinoma migration. Oncotarget, 2016, 7, 83554-83569.	0.8	44
241	Incidence and in-vivo relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon alpha-2a combined with acitretin or PUVA. Archives of Dermatological Research, 1996, 288, 543-548.	1.1	43
242	The immunohistochemistry of invasive and proliferative phenotype switching in melanoma: a case report. Melanoma Research, 2010, 20, 349-355.	0.6	43
243	Primary cutaneous lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 2008, 19, ii72-ii76.	0.6	42
244	Phase II Trial of Oral Panobinostat (LBH589) in Patients with Refractory Cutaneous T-Cell Lymphoma (CTCL).. Blood, 2008, 112, 1005-1005.	0.6	42
245	Formation of neutralizing antibodies against natural interferon-Î², but not against recombinant interferon-Î³ during adjuvant therapy for high-risk malignant melanoma patients. Cancer, 1991, 67, 2300-2304.	2.0	41
246	Intralesional Adenovirus-mediated Interleukin-2 Gene Transfer for Advanced Solid Cancers and Melanoma. Molecular Therapy, 2008, 16, 985-994.	3.7	41
247	Targeted therapy in melanoma â€” the role of BRAF, RAS and KIT mutations. European Journal of Cancer, Supplement, 2013, 11, 92-96.	2.2	41
248	SMAD signaling promotes melanoma metastasis independently of phenotype switching. Journal of Clinical Investigation, 2019, 129, 2702-2716.	3.9	41
249	An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases.. Journal of Clinical Oncology, 2011, 29, 8548-8548.	0.8	41
250	Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Swiss Medical Weekly, 2011, 141, w13320.	0.8	41
251	Role of Imiquimod in Skin Cancer Treatment. American Journal of Clinical Dermatology, 2004, 5, 453-458.	3.3	40
252	Nrf2 Activation Promotes Keratinocyte Survival during Early Skin Carcinogenesis via Metabolic Alterations. Cancer Research, 2015, 75, 4817-4829.	0.4	40

#	ARTICLE	IF	CITATIONS
253	A paracrine activin A- α 2 axis promotes squamous carcinogenesis via fibroblast reprogramming. <i>EMBO Molecular Medicine</i> , 2020, 12, e11466.	3.3	40
254	Type I IFN innate immune response to adenovirus-mediated IFN- β gene transfer contributes to the regression of cutaneous lymphomas. <i>Journal of Clinical Investigation</i> , 2007, 117, 2834-2846.	3.9	40
255	Androgen receptor functions as transcriptional repressor of cancer-associated fibroblast activation. <i>Journal of Clinical Investigation</i> , 2018, 128, 5531-5548.	3.9	40
256	A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9007-9007.	0.8	39
257	Swiss Guidelines for the Treatment and Follow-Up of Cutaneous Melanoma. <i>Dermatology</i> , 2001, 203, 75-80.	0.9	38
258	Phase II Clinical Trial of Intratumoral Application of TG1042 (Adenovirus-interferon- β) in Patients With Advanced Cutaneous T-cell Lymphomas and Multilesional Cutaneous B-cell Lymphomas. <i>Molecular Therapy</i> , 2010, 18, 1244-1247.	3.7	38
259	Systemic corticosteroids for subcutaneous panniculitis-like T-cell lymphoma. <i>British Journal of Dermatology</i> , 2014, 171, 891-894.	1.4	38
260	Case Report: Encephalitis, with Brainstem Involvement, Following Checkpoint Inhibitor Therapy in Metastatic Melanoma. <i>Oncologist</i> , 2017, 22, 749-753.	1.9	38
261	Association of <i>BRAF</i> V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma. <i>JAMA Oncology</i> , 2020, 6, 1256.	3.4	38
262	Data mining The Cancer Genome Atlas in the era of precision cancer medicine. <i>Swiss Medical Weekly</i> , 2015, 145, w14183.	0.8	38
263	Imiquimod Treatment Induces Expression of Opioid Growth Factor Receptor. <i>Clinical Cancer Research</i> , 2004, 10, 4959-4970.	3.2	37
264	Long-Term Recurrence Rate of Large and Difficult to Treat Cutaneous Squamous Cell Carcinomas after Superficial Radiotherapy. <i>Dermatology</i> , 2012, 224, 59-65.	0.9	37
265	Achievements and Challenges of Molecular Targeted Therapy in Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , 177-186.	1.8	37
266	Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries. <i>European Journal of Cancer</i> , 2018, 104, 201-209.	1.3	37
267	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 655-664.	5.1	37
268	Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Tj ETQq0 0 0 rgBT6/Overlook 10 Tf 50		
269	Telomerase Expression by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi. <i>Journal of Investigative Dermatology</i> , 2016, 136, 339-342.	0.3	36
270	A review of binimetinib for the treatment of mutant cutaneous melanoma. <i>Future Oncology</i> , 2017, 13, 1755-1766.	1.1	35

#	ARTICLE	IF	CITATIONS
271	Distinct Clinicopathological and Prognostic Features of Thin Nodular Primary Melanomas: An International Study from 17 Centers. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1314-1322.	3.0	35
272	The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma. <i>Swiss Medical Weekly</i> , 2016, 146, w14279.	0.8	35
273	Survival and Prognostic Factors in Patients with Brain Metastases from Malignant Melanoma. <i>Oncology Research and Treatment</i> , 2004, 27, 145-149.	0.8	34
274	Neurological complications of cancer immunotherapy. <i>Cancer Treatment Reviews</i> , 2021, 97, 102189.	3.4	34
275	Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in <i>NRAS</i> -mutant cutaneous melanoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 9500-9500.	0.8	34
276	Interferon resistance of cutaneous T-cell lymphoma-derived clonal T-helper 2 cells allows selective viral replication. <i>Blood</i> , 2001, 97, 523-527.	0.6	33
277	Oral, Esophageal and Cutaneous Lichen Ruber Planus Controlled with Alitretinoin: Case Report and Review of the Literature. <i>Dermatology</i> , 2013, 226, 302-310.	0.9	33
278	Efficacy and Safety of APO866 in Patients With Refractory or Relapsed Cutaneous T-Cell Lymphoma. <i>JAMA Dermatology</i> , 2016, 152, 837.	2.0	33
279	A practical guide to the handling and administration of talimogene laherparepvec in Europe. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3867-3880.	1.0	33
280	Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy. , 2020, 8, e001689.		33
281	SEREX identification of new tumour-associated antigens in cutaneous T-cell lymphoma. <i>British Journal of Dermatology</i> , 2004, 150, 252-258.	1.4	32
282	Tumour assessment in advanced melanoma: value of FDG-PET/CT in patients with elevated serum S-100B. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1366-1375.	3.3	32
283	Cutaneous malignant melanoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2008, 19, ii86-ii88.	0.6	32
284	A prospective clinical trial to assess lapatinib effects on cutaneous squamous cell carcinoma and actinic keratosis. <i>ESMO Open</i> , 2016, 1, e000003.	2.0	32
285	More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments. <i>European Journal of Cancer</i> , 2017, 75, 313-322.	1.3	32
286	A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1547-1559.	2.0	32
287	Blockade of programmed cell death protein 1 (PD-1) in SÅžary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation. <i>Oncolmmunology</i> , 2020, 9, 1738797.	2.1	32
288	Pathogenesis of Cutaneous Lymphomas. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2000, 19, 78-86.	1.6	32

#	ARTICLE	IF	CITATIONS
289	Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring <i>BRAF</i> V600 or <i>NRAS</i> mutations.. Journal of Clinical Oncology, 2012, 30, 8511-8511.	0.8	32
290	Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma.. Journal of Clinical Oncology, 2013, 31, 9028-9028.	0.8	32
291	Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.. Journal of Clinical Oncology, 2014, 32, LBA9008-LBA9008.	0.8	32
292	Approach to lymphoproliferative infiltrates of the skin. The difficult lesions. American Journal of Clinical Pathology, 1999, 111, S84-93.	0.4	32
293	A new live-cell biobank workflow efficiently recovers heterogeneous melanoma cells from native biopsies. Experimental Dermatology, 2015, 24, 377-380.	1.4	31
294	Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2. Molecular Cancer Therapeutics, 2015, 14, 2132-2142.	1.9	31
295	A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma. Neoplasia, 2018, 20, 218-225.	2.3	31
296	Sustained androgen receptor signaling is a determinant of melanoma cell growth potential and tumorigenesis. Journal of Experimental Medicine, 2021, 218, .	4.2	31
297	Therapy of Cutaneous Lymphoma – Current Practice and Future Developments. Oncology Research and Treatment, 2003, 26, 366-372.	0.8	30
298	HLA-G expression in basal cell carcinomas of the skin recurring after radiotherapy. Clinical and Experimental Dermatology, 2005, 30, 422-425.	0.6	30
299	Basal cell carcinomas in a tertiary referral centre: a systematic analysis. British Journal of Dermatology, 2014, 171, 1066-1072.	1.4	30
300	Sox2 is dispensable for primary melanoma and metastasis formation. Oncogene, 2017, 36, 4516-4524.	2.6	30
301	Activin promotes skin carcinogenesis by attraction and reprogramming of macrophages. EMBO Molecular Medicine, 2017, 9, 27-45.	3.3	30
302	Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with <i>BRAF</i> V600-mutant melanoma.. Journal of Clinical Oncology, 2021, 39, 9507-9507.	0.8	30
303	Interim analysis of a randomized, open-label phase 2 study of talimogene laherparepvec (T-VEC) neoadjuvant treatment (neotx) plus surgery (surgx) vs surgx for resectable stage IIIB-IVM1a melanoma (MEL).. Journal of Clinical Oncology, 2018, 36, 9508-9508.	0.8	30
304	Clinical and Therapeutic Aspects of Polymorphous Light Eruption. Dermatology, 2003, 207, 93-95.	0.9	29
305	Evaluation of lymphangiogenic markers in SÅzary syndrome. Leukemia and Lymphoma, 2011, 52, 491-501.	0.6	29
306	Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial. Journal of Clinical Oncology, 2015, 33, 4077-4084.	0.8	29

#	ARTICLE	IF	CITATIONS
307	Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma. <i>Annals of Oncology</i> , 2017, 28, v429-v430.	0.6	29
308	Ipilimumab and early signs of pulmonary toxicity in patients with metastatic melanoma: a prospective observational study. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 127-134.	2.0	29
309	Immunologic Characteristics of Nonmelanoma Skin Cancers: Implications for Immunotherapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 398-407.	1.8	29
310	Brief S2k guidelines "Cutaneous lymphomas. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 19-28.	0.4	28
311	Novel therapies for cutaneous T-cell lymphoma: what does the future hold?. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 457-467.	1.9	28
312	TG1042 (Adenovirus-interferon- β) in Primary Cutaneous B-cell Lymphomas: A Phase II Clinical Trial. <i>PLoS ONE</i> , 2014, 9, e83670.	1.1	28
313	PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas. <i>Oncotarget</i> , 2016, 7, 75551-75560.	0.8	28
314	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. <i>European Journal of Cancer</i> , 2022, 162, 22-33.	1.3	28
315	Hepatitis C and G viruses in B-cell lymphomas of the skin. <i>Journal of Cutaneous Pathology</i> , 2003, 30, 369-372.	0.7	27
316	Recombinant Measles Virus Induces Cytolysis of Cutaneous T-Cell Lymphoma In Vitro and In Vivo. <i>Journal of Investigative Dermatology</i> , 2006, 126, 2525-2532.	0.3	27
317	Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). <i>Annals of Oncology</i> , 2008, 19, 801-806.	0.6	27
318	Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate. <i>Melanoma Research</i> , 2008, 18, 104-111.	0.6	27
319	Melanoma immunotherapy: historical precedents, recent successes and future prospects. <i>Immunotherapy</i> , 2013, 5, 169-182.	1.0	27
320	Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?. <i>PLoS ONE</i> , 2015, 10, e0139438.	1.1	27
321	Histiocytosis "cutaneous manifestations of hematopoietic neoplasm and non-neoplastic histiocytic proliferations. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 926-934.	1.3	27
322	Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study. <i>Melanoma Research</i> , 2019, 29, 65-69.	0.6	27
323	Identification of miR-200a-5p targeting the peptide transporter TAP1 and its association with the clinical outcome of melanoma patients. <i>Oncolmmunology</i> , 2020, 9, 1774323.	2.1	27
324	Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications. <i>Cancer Treatment Reviews</i> , 2020, 88, 102060.	3.4	27

#	ARTICLE	IF	CITATIONS
325	Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. <i>European Journal of Cancer</i> , 2021, 148, 411-421.	1.3	27
326	Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. <i>European Journal of Cancer</i> , 2014, 50, 406-410.	1.3	26
327	Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation status. <i>British Journal of Dermatology</i> , 2016, 174, 823-830.	1.4	26
328	Proteomic identification of a marker signature for MAPK i resistance in melanoma. <i>EMBO Journal</i> , 2019, 38, e95874.	3.5	26
329	UV Protection and Skin Cancer. <i>Recent Results in Cancer Research</i> , 2002, 160, 7-12.	1.8	26
330	SÅzary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain). <i>Blood</i> , 1996, 88, 1383-9.	0.6	26
331	Recent advances in cutaneous lymphomas. <i>Journal of Dermatological Science</i> , 2007, 48, 157-167.	1.0	25
332	Integrating first-line treatment options into clinical practice. <i>Melanoma Research</i> , 2015, 25, 461-469.	0.6	25
333	NGS-pipe: a flexible, easily extendable and highly configurable framework for NGS analysis. <i>Bioinformatics</i> , 2018, 34, 107-108.	1.8	25
334	Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?. <i>Lancet Oncology</i> , The, 2018, 19, e720-e725.	5.1	25
335	Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect. <i>BMC Cancer</i> , 2020, 20, 300.	1.1	25
336	Cutaneous malignant lymphomas: Update 2006. <i>JDDG - Journal of the German Society of Dermatology</i> , 2006, 4, 914-933.	0.4	24
337	A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting. <i>British Journal of Dermatology</i> , 2015, 173, 1462-1470.	1.4	24
338	A single-dose mass balance and metabolite profiling study of vemurafenib in patients with metastatic melanoma. <i>Pharmacology Research and Perspectives</i> , 2015, 3, e00113.	1.1	24
339	A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. <i>Cancer Medicine</i> , 2017, 6, 1904-1914.	1.3	24
340	Flare-Up of Rheumatoid Arthritis by Anti-CTLA-4 Antibody but Not by Anti-PD1 Therapy in a Patient with Metastatic Melanoma. <i>Case Reports in Dermatology</i> , 2017, 9, 65-68.	0.3	24
341	Induction of the members of Notch pathway in superficial basal cell carcinomas treated with imiquimod. <i>Archives of Dermatological Research</i> , 2007, 299, 493-498.	1.1	23
342	Arsenic trioxide down-regulates antiapoptotic genes and induces cell death in mycosis fungoides tumors in a mouse model. <i>Annals of Oncology</i> , 2008, 19, 1488-1494.	0.6	23

#	ARTICLE	IF	CITATIONS
343	Cutaneous Drug Eruptions Associated with the Use of New Oncological Drugs. <i>Chemical Immunology and Allergy</i> , 2012, 97, 191-202.	1.7	23
344	Primary cutaneous follicle center lymphoma with diffuse CD30 expression: A report of 4 cases of a rare variant. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 548-554.	0.6	23
345	Transcriptional repression of IFN γ 1 by ATF2 confers melanoma resistance to therapy. <i>Oncogene</i> , 2015, 34, 5739-5748.	2.6	23
346	Efficacy and safety of oral alitretinoin in severe oral lichen planus – results of a prospective pilot study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 293-298.	1.3	23
347	A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K-mutant Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 5102-5112.	3.2	23
348	Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2242-2252.e7.	0.3	23
349	Temporal activation of WNT/ β -catenin signaling is sufficient to inhibit SOX10 expression and block melanoma growth. <i>Oncogene</i> , 2020, 39, 4132-4154.	2.6	23
350	Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 9504-9504.	0.8	23
351	The impact of COVID-19 on cancer care and oncology clinical research: an experts' perspective. <i>ESMO Open</i> , 2022, 7, 100339.	2.0	23
352	About Moles, Melanomas, and Lasers. <i>Archives of Dermatology</i> , 2003, 139, 1405-6.	1.7	22
353	Consequences of p16 tumor suppressor gene inactivation in mycosis fungoides and Sezary syndrome and role of the bmi-1 and ras oncogenes in disease progression. <i>Human Pathology</i> , 2007, 38, 995-1002.	1.1	22
354	Combined treatment with pegylated interferon α 2a and dacarbazine in patients with advanced metastatic melanoma. <i>Cancer</i> , 2008, 113, 1404-1411.	2.0	22
355	New and Experimental Skin-Directed Therapies for Cutaneous Lymphomas. <i>Skin Pharmacology and Physiology</i> , 2009, 22, 322-334.	1.1	22
356	Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1087-1099.	1.4	22
357	Recent advances in primary cutaneous T-cell lymphoma. <i>Current Opinion in Oncology</i> , 2015, 27, 128-133.	1.1	22
358	Pathogenesis of cutaneous lymphomas. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2000, 19, 78-86.	1.6	22
359	Primary Localization and Tumor Thickness as Prognostic Factors of Survival in Patients with Mucosal Melanoma. <i>PLoS ONE</i> , 2014, 9, e112535.	1.1	22
360	Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. <i>Annals of Oncology</i> , 2022, 33, 968-980.	0.6	22

#	ARTICLE	IF	CITATIONS
361	A Transcriptionally Inactive ATF2 Variant Drives Melanomagenesis. <i>Cell Reports</i> , 2016, 15, 1884-1892.	2.9	21
362	Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment. <i>Journal of Immunotherapy</i> , 2019, 42, 89-93.	1.2	21
363	Increased tumour cell <sc>PD</sc>â€1 expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 667-675.	1.3	21
364	Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. <i>European Journal of Cancer</i> , 2020, 133, 120-130.	1.3	21
365	mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition. <i>Oncotarget</i> , 2017, 8, 69204-69218.	0.8	21
366	Cost-effectiveness of whole-body PET imaging in non-small cell lung cancer and malignant melanoma. <i>Academic Radiology</i> , 1998, 5, S300-S302.	1.3	20
367	Prevention Campaign against Skin Cancer. <i>Dermatology</i> , 2002, 205, 229-233.	0.9	20
368	Laser treatment of solar lentigines on dorsum of hands: QS Ruby laser versus ablative CO2 fractional laser â€ a randomized controlled trial. <i>European Journal of Dermatology</i> , 2015, 25, 122-126.	0.3	20
369	Versican upregulation in SÃ©zary cells alters growth, motility and resistance to chemotherapy. <i>Leukemia</i> , 2015, 29, 2024-2032.	3.3	20
370	Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland. <i>Melanoma Research</i> , 2017, 27, 358-368.	0.6	20
371	Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma. <i>ESMO Open</i> , 2020, 5, e000763.	2.0	20
372	Malignant blue naevus with distant subcutaneous metastasis. <i>Clinical and Experimental Dermatology</i> , 1996, 21, 427-430.	0.6	19
373	Emerging drugs and combination strategies for basal cell carcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 353-365.	1.0	19
374	Adverse events 2.0â€Let us get SERIOs. <i>European Journal of Cancer</i> , 2019, 112, 29-31.	1.3	19
375	Pharmacokineticâ€pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies. <i>British Journal of Cancer</i> , 2021, 125, 687-698.	2.9	19
376	Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis. <i>Cancers</i> , 2021, 13, 2931.	1.7	19
377	Resilience in patients and spouses faced with malignant melanoma. A qualitative longitudinal study. <i>European Journal of Cancer Care</i> , 2016, 25, 122-131.	0.7	18
378	SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinics. <i>BMC Medical Informatics and Decision Making</i> , 2018, 18, 89.	1.5	18

#	ARTICLE	IF	CITATIONS
379	Identification of microRNAs Targeting the Transporter Associated with Antigen Processing TAP1 in Melanoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 2690.	1.0	18
380	Clinical diversity and treatment approaches to blastic plasmacytoid dendritic cell neoplasm: a retrospective multicentre study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1489-1495.	1.3	18
381	Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2015, 33, 3012-3012.	0.8	18
382	Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9523-9523.	0.8	18
383	The safety of anti PD-1 therapeutics for the treatment of melanoma. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 41-53.	1.0	17
384	Diagnostic value of 18F-fluorodesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site. <i>European Journal of Cancer</i> , 2018, 96, 64-72.	1.3	17
385	The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis. <i>Journal of Dermatological Science</i> , 2018, 90, 343-356.	1.0	17
386	Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases. <i>Clinical Proteomics</i> , 2018, 15, 13.	1.1	17
387	The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in rapidly accelerated fibrosarcoma-mutated advanced melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 686-692.	1.3	17
388	Retrospective Analysis of Treatment and Complications of Immune Checkpoint Inhibitor-Associated Colitis: Histological Ulcerations as Potential Predictor for a Steroid-Refractory Disease Course. <i>Inflammatory Intestinal Diseases</i> , 2020, 5, 109-116.	0.8	17
389	Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9524-9524.	0.8	17
390	Nevoid Basal Cell Carcinoma Syndrome: Report from the Zurich Nevoid Basal Cell Carcinoma Syndrome Cohort. <i>Dermatology</i> , 2016, 232, 285-292.	0.9	16
391	Metastatic melanoma moves on: translational science in the era of personalized medicine. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 7-21.	2.7	16
392	ADAMTSL5 is upregulated in melanoma tissues in patients with idiopathic psoriasis vulgaris induced by nivolumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e100-e101.	1.3	16
393	Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced KRAS- or BRAF-mutated melanoma. <i>Oncotarget</i> , 2019, 10, 1850-1859.	0.8	16
394	Evaluation of the minimal erythema dose for UVB and UVA in context of skin phototype and nature of photodermatosis. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2020, 36, 200-207.	0.7	16
395	Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAJORIC trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2225-2238.	1.3	16
396	Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid. <i>Archives of Dermatological Research</i> , 1996, 288, 353-357.	1.1	16

#	ARTICLE	IF	CITATIONS
397	Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study. <i>European Journal of Dermatology</i> , 2018, 28, 775-783.	0.3	16
398	HLA-G in skin cancer: a wolf in sheep's clothing?. <i>Human Immunology</i> , 2003, 64, 1073-1080.	1.2	15
399	Standard and experimental therapy in cutaneous T-cell lymphomas. <i>Journal of Cutaneous Pathology</i> , 2006, 33, 52-57.	0.7	15
400	Future Perspectives in the Treatment of Cutaneous T-Cell Lymphoma (CTCL). <i>Seminars in Oncology</i> , 2006, 33, 33-36.	0.8	15
401	Split-face study of melasma patients treated with non-ablative fractionated photothermolysis (1540nm). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 423-430.	1.3	15
402	Basal cell carcinoma: a paradigm for targeted therapies. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1307-1318.	0.9	15
403	Clinical implications of distinct metastasizing preferences of different melanoma subtypes. <i>European Journal of Dermatology</i> , 2014, 24, 236-241.	0.3	15
404	An Aggressive Hypoxia Related Subpopulation of Melanoma Cells is TRP-2 Negative. <i>Translational Oncology</i> , 2014, 7, 206-212.	1.7	15
405	Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching?. <i>Melanoma Research</i> , 2017, 27, 231-237.	0.6	15
406	Dose-escalation study evaluating pegylated interferon alpha-2a in patients with cutaneous T-cell lymphoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1841-1847.	1.3	15
407	MEK inhibition and immune responses in advanced melanoma. <i>Oncolmmunology</i> , 2017, 6, e1335843.	2.1	15
408	Keratinocytic Malfunction as a Trigger for the Development of Solar Lentiginos. <i>Dermatopathology (Basel, Switzerland)</i> , 2019, 6, 1-11.	0.7	15
409	A Monocentric, Retrospective Analysis of 61 Patients with Generalized Granuloma Annulare. <i>Dermatology</i> , 2020, 236, 369-374.	0.9	15
410	Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4. <i>Nature Communications</i> , 2021, 12, 5056.	5.8	15
411	Establishing standardized immune phenotyping of metastatic melanoma by digital pathology. <i>Laboratory Investigation</i> , 2021, 101, 1561-1570.	1.7	15
412	The utility of chemotherapy after immunotherapy failure in metastatic melanoma: A multicenter case series.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21588-e21588.	0.8	15
413	Cutaneous T-Cell Lymphomas: Prognosis and Quality-of-Life Issues. <i>Clinical Lymphoma and Myeloma</i> , 2000, 1, S21-S25.	2.1	14
414	Spindle-cell variant of primary cutaneous follicle center lymphoma spreading to the hepatobiliary tree, mimicking Klatskin tumor. <i>Journal of Cutaneous Pathology</i> , 2013, 40, 56-60.	0.7	14

#	ARTICLE	IF	CITATIONS
415	Sonidegib for the treatment of advanced basal cell carcinoma. Expert Opinion on Pharmacotherapy, 2016, 17, 1963-1968.	0.9	14
416	Noncutaneous Melanomas: A Single-Center Analysis. Dermatology, 2016, 232, 22-29.	0.9	14
417	Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1977-1984.	1.2	14
418	Metastatic acral lentiginous melanoma in a tertiary referral center in Switzerland: a systematic analysis. Melanoma Research, 2018, 28, 442-450.	0.6	14
419	Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update. Expert Opinion on Investigational Drugs, 2019, 28, 799-809.	1.9	14
420	Efficacy and Safety of Sonidegib in Adult Patients with Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome): Results from a Phase 2, Double-Blind, Randomized Trial. Clinical, Cosmetic and Investigational Dermatology, 2020, Volume 13, 117-121.	0.8	14
421	METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM).. Journal of Clinical Oncology, 2012, 30, LBA8509-LBA8509.	0.8	14
422	Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.. Journal of Clinical Oncology, 2014, 32, LBA9008-LBA9008.	0.8	14
423	Impact of treatment breaks on vismodegib patient outcomes: Exploratory analysis of the STEVIE study.. Journal of Clinical Oncology, 2015, 33, 9024-9024.	0.8	14
424	A phase I study of LXH254 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.. Journal of Clinical Oncology, 2018, 36, 2586-2586.	0.8	14
425	Prognostic significance of DNA cytometry in cutaneous malignant lymphomas. Cancer, 1991, 68, 1095-1100.	2.0	13
426	Inverse regulation of neuronal cellular adhesion molecule (NCAM) by IFN- γ in melanoma cell cultures established from CNS lesions. , 1999, 83, 135-140.		13
427	Baseline Staging of Melanoma with Unknown Primary Site: The Value of Serum S100 Protein and Positron Emission Tomography. Dermatology, 2008, 217, 351-355.	0.9	13
428	Metastatic melanoma cell lines do not secrete IL-1 β but promote IL-1 β production from macrophages. Journal of Dermatological Science, 2014, 74, 167-169.	1.0	13
429	The role of cyclin D1 and Ki67 in the development and prognostication of thin melanoma. Histopathology, 2020, 77, 460-470.	1.6	13
430	SPANX Control of Lamin A/C Modulates Nuclear Architecture and Promotes Melanoma Growth. Molecular Cancer Research, 2020, 18, 1560-1573.	1.5	13
431	A multicentre study of naevus-associated melanoma vs. <i>de novo</i> melanoma, tumour thickness and body site differences*. British Journal of Dermatology, 2021, 185, 101-109.	1.4	13
432	429...Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma. , 2020, 8, A454-A454.		13

#	ARTICLE	IF	CITATIONS
433	METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS) compared with chemotherapy (C) in patients (pts) with BRAFV600/k mutant advanced or metastatic melanoma (MM).. Journal of Clinical Oncology, 2012, 30, LBA8509-LBA8509.	0.8	13
434	Granulomatous Slack Skin Responds to UVA1 Phototherapy. Dermatology, 2009, 219, 268-271.	0.9	12
435	<i>In vivo</i> profiling reveals immunomodulatory effects of sorafenib and dacarbazine on melanoma. OncoImmunology, 2015, 4, e988458.	2.1	12
436	Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600 mutated melanoma. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1638-1640.	1.3	12
437	Aggressive Rare T-cell Lymphomas with Manifestation in the Skin: A Monocentric Cross-sectional Case Study. Acta Dermato-Venereologica, 2018, 98, 835-841.	0.6	12
438	Improved detection of in-transit metastases of malignant melanoma with BSREM reconstruction in digital [18F]FDG PET/CT. European Radiology, 2021, 31, 8011-8020.	2.3	12
439	Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response. European Journal of Cancer, 2021, 149, 37-48.	1.3	12
440	Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients. Cancers, 2021, 13, 3830.	1.7	12
441	Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study. Blood, 2016, 128, 182-182.	0.6	12
442	Correlation between metastatic site and response to anti-Programmed Death-1 (PD-1) agents in melanoma.. Journal of Clinical Oncology, 2016, 34, 9549-9549.	0.8	12
443	The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases – A multicenter cohort study. European Journal of Cancer, 2022, 169, 210-222.	1.3	12
444	Cutaneous Lymphomas: Molecular Pathways Leading to New Drugs. Journal of Investigative Dermatology, 2012, 132, 517-525.	0.3	11
445	Melanoma's next top model, it is in the air. Experimental Dermatology, 2015, 24, 659-660.	1.4	11
446	Radiotherapy in Periocular Cutaneous Malignancies: A Retrospective Study. Dermatology, 2019, 235, 234-239.	0.9	11
447	Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases. European Journal of Cancer, 2021, 156, 149-163.	1.3	11
448	Systemic inflammatory reaction syndrome during combined kinase inhibitor therapy following anti-PD-1 therapy for melanoma. Annals of Oncology, 2017, 28, 1673-1675.	0.6	11
449	How cutaneous eruptions help to understand the mode of action of kinase inhibitors. British Journal of Dermatology, 2012, 167, 965-967.	1.4	10
450	Lymphocytic infiltration in the cutaneous lymphoma microenvironment after injection of TG1042. Journal of Translational Medicine, 2013, 11, 226.	1.8	10

#	ARTICLE	IF	CITATIONS
451	HLA-A*26 Is Correlated With Response to Nivolumab in Japanese Melanoma Patients. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2443-2444.	0.3	10
452	Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma. <i>European Journal of Cancer</i> , 2018, 93, 147-149.	1.3	10
453	Potassium Iodide for Cutaneous Inflammatory Disorders: A Monocentric, Retrospective Study. <i>Dermatology</i> , 2019, 235, 137-143.	0.9	10
454	The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions. <i>European Journal of Cancer</i> , 2020, 138, 68-76.	1.3	10
455	Abstract CT002: Phase 3 randomized trial comparing tebentafusp with investigator's choice in first line metastatic uveal melanoma. <i>Cancer Research</i> , 2021, 81, CT002-CT002.	0.4	10
456	Vorinostat in combination with bexarotene in advanced cutaneous T-cell lymphoma: A phase I study. <i>Journal of Clinical Oncology</i> , 2009, 27, 8572-8572.	0.8	10
457	Long-term pegylated interferon-alpha and its potential in the treatment of melanoma. <i>Biologics: Targets and Therapy</i> , 2009, 3, 169-82.	3.0	10
458	Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor. <i>Clinical Cancer Research</i> , 2022, 28, 770-780.	3.2	10
459	Elastosis colloidalis conglomerata (adult colloid milium, paracolloid of the skin): a maximal manifestation of actinic elastosis?. <i>European Journal of Dermatology</i> , 2006, 16, 163-6.	0.3	10
460	Effects of COVID-19 Lockdown on Melanoma Diagnosis in Switzerland: Increased Tumor Thickness in Elderly Females and Shift towards Stage IV Melanoma during Lockdown. <i>Cancers</i> , 2022, 14, 2360.	1.7	10
461	Immunomodulators in the treatment of cutaneous lymphoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 1999, 13, 83-90.	1.3	9
462	Combination of Bexarotene and Psoralen-UVA Therapy in a Patient with Mycosis fungoides. <i>Dermatology</i> , 2004, 209, 72-74.	0.9	9
463	Cutaneous melanoma: uncommon presentations. <i>Clinics in Dermatology</i> , 2005, 23, 587-592.	0.8	9
464	Basal cell carcinomas: molecular abnormalities and molecularly targeted therapies. <i>Expert Review of Dermatology</i> , 2009, 4, 355-369.	0.3	9
465	Morpho-Molecular Assessment Indicates New Prognostic Aspects and Personalized Therapeutic Options in Sinonasal Melanoma. <i>Cancers</i> , 2019, 11, 1329.	1.7	9
466	Activation of CD8+ T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors. <i>Cancer Immunology Research</i> , 2020, 8, 1114-1121.	1.6	9
467	Long-Term Response to Intermittent Binimetinib in Patients with NRAS Mutant Melanoma. <i>Oncologist</i> , 2020, 25, e1593-e1597.	1.9	9
468	How to break resistance to hedgehog inhibitors in advanced basal cell carcinoma?. <i>British Journal of Dermatology</i> , 2021, 184, 359-361.	1.4	9

#	ARTICLE	IF	CITATIONS
469	The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma. <i>European Journal of Cancer</i> , 2021, 144, 215-223.	1.3	9
470	A multicenter, open-label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB-IV melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS9081-TPS9081.	0.8	9
471	Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2S310F mutated extramammary Paget's disease. <i>Oncotarget</i> , 2019, 10, 6647-6650.	0.8	9
472	Effects of Sonidegib Following Dose Reduction and Treatment Interruption in Patients with Advanced Basal Cell Carcinoma During 42-Month BOLT Trial. <i>Dermatology and Therapy</i> , 2021, 11, 2225-2234.	1.4	9
473	GVAX (Cell Genesys). <i>Current Opinion in Investigational Drugs</i> , 2001, 2, 844-8.	2.3	9
474	STARBOARD: encorafenib+binimetinib+ pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma. <i>Future Oncology</i> , 2022, 18, 2041-2051.	1.1	9
475	Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i). , 2022, 10, e004226.		9
476	T cells migrate to tumour sites after extracorporeal interleukin 2 stimulation and reinfusion in a patient with metastatic melanoma. <i>British Journal of Dermatology</i> , 1993, 128, 399-403.	1.4	8
477	Expression of melanoma-associated antigens in short-term melanoma cultures detected by RT-PCR and subsequent ELISA. <i>Archives of Dermatological Research</i> , 1998, 290, 458-461.	1.1	8
478	Emerging drugs in cutaneous T-cell lymphomas. <i>Expert Opinion on Emerging Drugs</i> , 2005, 10, 381-392.	1.0	8
479	Pathogenesis and therapy of cutaneous lymphomas ? Progress or impasse?. <i>Experimental Dermatology</i> , 2006, 15, 392-400.	1.4	8
480	S2k Kurzleitlinie " Kutane Lymphome. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 20-30.	0.4	8
481	3310 LOGIC2: Phase 2, multi-center, open-label study of sequential encorafenib/binimetinib combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally-advanced or metastatic BRAF V600 melanoma. <i>European Journal of Cancer</i> , 2015, 51, S667-S668.	1.3	8
482	An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel. <i>British Journal of Dermatology</i> , 2016, 175, 966-978.	1.4	8
483	appendix 2: Cutaneous melanoma (2): eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Melanoma). <i>Annals of Oncology</i> , 2016, 27, v136-v137.	0.6	8
484	Localized Hair Repigmentation in a 91-Year-Old Woman. <i>JAMA Dermatology</i> , 2016, 152, 81.	2.0	8
485	Serum S100B Levels in Melanoma. <i>Methods in Molecular Biology</i> , 2019, 1929, 691-700.	0.4	8
486	Osteoblasts contribute to a protective niche that supports melanoma cell proliferation and survival. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 74-85.	1.5	8

#	ARTICLE	IF	CITATIONS
487	Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy. <i>Radiation Oncology</i> , 2020, 15, 135.	1.2	8
488	Targeting complex, adaptive responses in melanoma therapy. <i>Cancer Treatment Reviews</i> , 2020, 86, 101997.	3.4	8
489	Efficacy and safety of colchicine in inflammatory skin diseases: a retrospective, monocentric study in a large tertiary center. <i>Journal of Dermatological Treatment</i> , 2021, 32, 104-109.	1.1	8
490	Single-center real-life experience with low-dose ipilimumab monotherapy in adjuvant setting for patients with stage III melanoma. <i>Melanoma Research</i> , 2019, 29, 648-654.	0.6	8
491	Cutaneous T-cell lymphoma: from genetics to clinical practice. <i>Oncology</i> , 2007, 21, 7-8.	0.4	8
492	Human Melanoma-Associated Mast Cells Display a Distinct Transcriptional Signature Characterized by an Upregulation of the Complement Component 3 That Correlates With Poor Prognosis. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	8
493	Eight Years of Real-Life Experience with Smoothed Inhibitors in a Swiss Tertiary Skin Referral Center. <i>Cancers</i> , 2022, 14, 2496.	1.7	8
494	Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-derived dendritic cells. , 2022, 10, e004268.		8
495	Erysipelas melanomatosum. <i>British Journal of Dermatology</i> , 1997, 137, 833-834.	1.4	7
496	Immunomodulators in the treatment of cutaneous lymphomas. <i>Expert Opinion on Biological Therapy</i> , 2002, 2, 279-286.	1.4	7
497	Cutaneous lymphomas. <i>JDDG - Journal of the German Society of Dermatology</i> , 2007, 5, 605-617.	0.4	7
498	Cutaneous squamous cell carcinomas on special locations: perioral, periocular and genital area. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 21-24.	1.3	7
499	Innovative Therapeutic Approaches in Primary Cutaneous B Cell Lymphoma. <i>Frontiers in Oncology</i> , 2020, 10, 1163.	1.3	7
500	Long-term Disease Control After Allogeneic Hematopoietic Stem Cell Transplantation in Primary Cutaneous T-cell Lymphoma; Results From a Single Institution Analysis. <i>Frontiers in Medicine</i> , 2020, 7, 290.	1.2	7
501	Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes With LDE225 Treatment (BOLT) trial at 42 months. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1162-1164.	0.6	7
502	Overall survival benefit from tebentafusp in patients with best response of progressive disease.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9509-9509.	0.8	7
503	Who's Driving? Switch of Drivers in Immunotherapy-Treated Progressing Sinonasal Melanoma. <i>Cancers</i> , 2021, 13, 2725.	1.7	7
504	Clinicopathological and Genomic Profiles of Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma Identify Overlapping Signatures with a High Mutational Burden. <i>Genes</i> , 2021, 12, 974.	1.0	7

#	ARTICLE	IF	CITATIONS
505	Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). <i>European Journal of Cancer</i> , 2021, 152, 116-128.	1.3	7
506	Specific Activation of the CD271 Intracellular Domain in Combination with Chemotherapy or Targeted Therapy Inhibits Melanoma Progression. <i>Cancer Research</i> , 2021, 81, 6044-6057.	0.4	7
507	Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis. <i>BMC Cancer</i> , 2021, 21, 1244.	1.1	7
508	A DNA replication-independent function of pre-replication complex genes during cell invasion in <i>C. elegans</i> . <i>PLoS Biology</i> , 2022, 20, e3001317.	2.6	7
509	Clinical Experience: Practical Management of Five Patients With Cutaneous T-Cell Lymphoma (CTCL)-Related Symptoms. <i>Seminars in Oncology</i> , 2006, 33, 26-32.	0.8	6
510	Analysis of adenovirus trans-complementation-mediated gene expression controlled by melanoma-specific TETP promoter in vitro. <i>Virology Journal</i> , 2010, 7, 175.	1.4	6
511	Recent Advances in the Management of Cutaneous Lymphomas. <i>Seminars in Oncology</i> , 2012, 39, 150-162.	0.8	6
512	Less can be more: the impact of chemotherapy on cutaneous T-cell lymphomas. <i>Future Oncology</i> , 2013, 9, 1061-1064.	1.1	6
513	Real-life Experience With Pegylated Interferon and Conventional Interferon in Adjuvant Melanoma Therapy. <i>Journal of Immunotherapy</i> , 2013, 36, 52-56.	1.2	6
514	Intratumoral Heterogeneity of MAGE-C1/CT7 and MAGE-C2/CT10 Expression in Mucosal Melanoma. <i>BioMed Research International</i> , 2015, 2015, 1-5.	0.9	6
515	Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, With Bilateral Intraocular Involvement and Infiltration to the CNS. <i>Journal of Clinical Oncology</i> , 2016, 34, e93-e96.	0.8	6
516	Binimetinib in heavily pretreated patients with NRAS μ mutant melanoma with brain metastases. <i>British Journal of Dermatology</i> , 2020, 182, 488-490.	1.4	6
517	NRAS ^{Q61K} melanoma tumor formation is reduced by p38 α -MAPK14 activation in zebrafish models and NRAS μ mutated human melanoma cells. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 150-162.	1.5	6
518	Clinical and Molecular Features of Skin Malignancies in Muir-Torre Syndrome. <i>Genes</i> , 2021, 12, 781.	1.0	6
519	A phase 1/3 multicenter trial of talimogene laherparepvec in combination with pembrolizumab for unresected, stage IIIB-IV melanoma (MASTERKEY-265).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS9598-TPS9598.	0.8	6
520	Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe. <i>European Journal of Dermatology</i> , 2018, 28, 736-749.	0.3	6
521	External beam radiotherapy of extramammary Paget disease. <i>Cutis</i> , 2015, 95, 109-12.	0.4	6
522	Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma. <i>Cancers</i> , 2022, 14, 2300.	1.7	6

#	ARTICLE	IF	CITATIONS
523	Soluble interleukin-2 receptors and cutaneous t-cell lymphoma. <i>Cancer</i> , 1993, 71, 3793-3795.	2.0	5
524	Melanoma Vaccines in Development. <i>BioDrugs</i> , 2000, 13, 227-231.	2.2	5
525	Primary cutaneous lymphomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2007, 18, ii61-ii62.	0.6	5
526	Reduced pSmad2 immunodetection correlates with increased primary melanoma thickness. <i>Melanoma Research</i> , 2007, 17, 131-136.	0.6	5
527	How Melanoma Is Treated in Real Life. <i>Archives of Dermatology</i> , 2008, 144, 664-5.	1.7	5
528	Successful treatment of multiple keratoacanthoma with topical imiquimod and low-dose acitretin. <i>Journal of Dermatology</i> , 2011, 38, 390-392.	0.6	5
529	Curing advanced melanoma by 2025. <i>Current Opinion in Oncology</i> , 2015, 27, 125-127.	1.1	5
530	Angioimmunoblastic T-Cell Lymphoma Mimicking Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome). <i>Case Reports in Dermatology</i> , 2017, 9, 74-79.	0.3	5
531	Oestrogen receptor expression in melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1399-1400.	1.3	5
532	Critical aspects to achieve a high-quality melanoma clinic. <i>Current Opinion in Oncology</i> , 2017, 29, 145-150.	1.1	5
533	Methadone-Not a magic bullet in melanoma therapy. <i>Experimental Dermatology</i> , 2018, 27, 694-696.	1.4	5
534	Vismodegib for recurrent locally destructive basal cell carcinoma in a renal transplant patient. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e7-e8.	1.3	5
535	Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma. <i>ESMO Open</i> , 2018, 3, e000388.	2.0	5
536	Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis. <i>Melanoma Research</i> , 2020, 30, 552-561.	0.6	5
537	Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019). <i>TJ ETQq1_1</i> 0.784314 rgBT (1.8	5
538	Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1119-1132.	1.3	5
539	Is single versus combination therapy problematic in the treatment of cutaneous melanoma?. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 9-23.	1.3	5
540	432-3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma. , 2020, 8, A458-A458.		5

#	ARTICLE	IF	CITATIONS
541	SECOMBIT (sequential combo immuno and target therapy study): A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy [ipilimumab (I)/nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with metastatic melanoma and BRAF mutation.. Journal of Clinical Oncology, 2017, 35, TPS9598-TPS9598.	0.8	5
542	A prognostic gene-signature based identification of high-risk thin melanomas.. Journal of Clinical Oncology, 2018, 36, e21575-e21575.	0.8	5
543	STK11 Prevents Invasion through Signal Transducer and Activator of Transcription 3/5 and FAK Repression in Cutaneous Melanoma. Journal of Investigative Dermatology, 2022, 142, 1171-1182.e10.	0.3	5
544	Cutaneous SCC with orbital invasion: case series. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 59-62.	1.3	5
545	Peripheral blood mononuclear cells in patients with nonleukemic cutaneous T-cell lymphoma. Reduced proliferation and preferential secretion of a T helper-2-like cytokine pattern on stimulation. Archives of Dermatology, 1993, 129, 433-6.	1.7	5
546	Using drug scheduling to manage adverse events associated with hedgehog pathway inhibitors for basal cell carcinoma. Oncotarget, 2021, 12, 2531-2540.	0.8	5
547	Development of a core outcome set for basal cell carcinoma. Journal of the American Academy of Dermatology, 2022, 87, 573-581.	0.6	5
548	Comment on "Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines". European Journal of Cancer, 2020, 131, 100-103.	1.3	4
549	Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer. , 2020, 8, e001607.		4
550	Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Final analysis of a randomized phase III DeCOG-trial (NCT00226408).. Journal of Clinical Oncology, 2012, 30, 8505-8505.	0.8	4
551	Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: Association with overall survival?. Journal of Clinical Oncology, 2013, 31, 9025-9025.	0.8	4
552	Model-based analysis of the relationship between pembrolizumab (MK-3475) exposure and efficacy in patients with advanced or metastatic melanoma.. Journal of Clinical Oncology, 2015, 33, 3068-3068.	0.8	4
553	Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study.. Journal of Clinical Oncology, 2017, 35, 7517-7517.	0.8	4
554	Time to next treatment in patients with previously treated cutaneous T-cell lymphoma (CTCL) receiving mogamulizumab or vorinostat: A MAVORIC post-hoc analysis.. Journal of Clinical Oncology, 2019, 37, 7539-7539.	0.8	4
555	Melanoma patients with additional primary cancers: a single-center retrospective analysis. Oncotarget, 2019, 10, 3373-3384.	0.8	4
556	Characterizing CD44 regulatory microRNAs as putative therapeutic agents in human melanoma. Oncotarget, 2019, 10, 6509-6525.	0.8	4
557	Results of a 10-year web-based health promotion campaign against skin cancer in Switzerland. European Journal of Dermatology, 2021, 31, 530-537.	0.3	4
558	Radiotherapy as a Treatment Option for Local Disease Control in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. Dermatology, 2022, 238, 967-976.	0.9	4

#	ARTICLE	IF	CITATIONS
559	Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with <i>BRAF</i> ^{V600} mutation-“positive melanoma with central nervous system (CNS) metastases (mets): Primary results from phase 2 Tricotel study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9515-9515.	0.8	4
560	Precision medicine and skin cancer therapy. <i>Current Opinion in Oncology</i> , 2014, 26, 182-183.	1.1	3
561	New Diagnostic Method for Lesions With Transepidermal Melanocytic Migration. <i>JAMA Dermatology</i> , 2014, 150, 654.	2.0	3
562	Coexpression of SOX10/CD271 (p75 ^{NTR}) and β -Galactosidase in Large to Giant Congenital Melanocytic Nevi of Pediatric Patients. <i>Dermatopathology (Basel, Switzerland)</i> , 2014, 1, 35-46.	0.7	3
563	TIME TO NEXT TREATMENT IN PATIENTS WITH PREVIOUSLY TREATED CUTANEOUS T-CELL LYMPHOMA (CTCL) RECEIVING MOGAMULIZUMAB OR VORINOSTAT: A POST-HOC ANALYSIS OF THE MAVORIC STUDY. <i>Hematological Oncology</i> , 2019, 37, 285-286.	0.8	3
564	Evaluation of the Interplay between the ADAR Editome and Immunotherapy in Melanoma. <i>Non-coding RNA</i> , 2021, 7, 5.	1.3	3
565	Malignancy Rate of Indeterminate Findings on FDG-PET/CT in Cutaneous Melanoma Patients. <i>Diagnostics</i> , 2021, 11, 883.	1.3	3
566	Standardized diagnostic algorithm for spitzoid lesions aids clinical decision-making and management: a case series from a Swiss reference center. <i>Oncotarget</i> , 2021, 12, 125-130.	0.8	3
567	Cutaneous side effects (cAE) of vemurafenib (V): Single-center cohort study of 28 metastatic melanoma (mM) patients (pts).. <i>Journal of Clinical Oncology</i> , 2012, 30, e19017-e19017.	0.8	3
568	The peripheral blood TCR repertoire to facilitate patient stratification for immune checkpoint blockade inhibition in metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3026-3026.	0.8	3
569	Vismodegib (VISMO), a hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study primary analysis in 1215 patients (pts).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9532-9532.	0.8	3
570	Adverse events of special interest in the phase 3 COLUMBUS study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9567-9567.	0.8	3
571	Targeted treatment of advanced NRAS-mutated melanoma. <i>Oncotarget</i> , 2017, 8, 84616-84617.	0.8	3
572	Pathology of cutaneous T-cell lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 1995, 9, 961-95.	0.9	3
573	Loss of YY1, a Regulator of Metabolism in Melanoma, Drives Melanoma Cell Invasiveness and Metastasis Formation. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	3
574	Soluble interleukin-2 receptors and psoriasis. <i>Archives of Dermatological Research</i> , 1991, 283, 138-139.	1.1	2
575	Diagnostic signs of cutaneous lymphomas. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2001, 15, 358-360.	1.3	2
576	CTCL - a tumour of skin homing T-cells. <i>Experimental Dermatology</i> , 2002, 11, 483-484.	1.4	2

#	ARTICLE	IF	CITATIONS
577	Long-term pegylated interferon-α and its potential in the treatment of melanoma. <i>Biologics: Targets and Therapy</i> , 2009, , 169.	3.0	2
578	Treating basal-cell carcinoma in a real life setting. <i>Lancet Oncology</i> , The, 2013, 14, 572-573.	5.1	2
579	Treatment specific utility-weightings are needed for cost-utility analysis in metastatic melanoma: reply from the authors. <i>British Journal of Dermatology</i> , 2016, 174, 463-463.	1.4	2
580	BRENTUXIMAB VEDOTIN VS PHYSICIAN'S CHOICE IN CTCL PATIENTS FROM THE PHASE 3 ALCANZA STUDY: ANALYSIS OF OUTCOMES BY CD30 EXPRESSION. <i>Hematological Oncology</i> , 2017, 35, 77-78.	0.8	2
581	PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA: RESULTS FROM THE PHASE 3 ALCANZA STUDY. <i>Hematological Oncology</i> , 2017, 35, 247-248.	0.8	2
582	FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30-POSITIVE (CD30+) CUTANEOUS T-CELL LYMPHOMA (CTCL). <i>Hematological Oncology</i> , 2019, 37, 286-288.	0.8	2
583	Rapidly Evolving Extensive Fluorodeoxyglucose-Positive Soft-Tissue Activity During Nivolumab Therapy. <i>JAMA Oncology</i> , 2019, 5, 730.	3.4	2
584	How I treat metastatic melanoma. <i>ESMO Open</i> , 2019, 4, e000509.	2.0	2
585	Dapsone in a Large Tertiary Center: Outdated Therapeutic Option or Timeless Agent?. <i>Dermatology</i> , 2020, 236, 183-190.	0.9	2
586	Laser Treatment of Accidental Tattoos: Experience at a Tertiary Referral Center. <i>Dermatology</i> , 2020, 236, 383-389.	0.9	2
587	Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG). <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1763-1771.	1.2	2
588	Lung Nodules in Melanoma Patients: Morphologic Criteria to Differentiate Non-Metastatic and Metastatic Lesions. <i>Diagnostics</i> , 2021, 11, 837.	1.3	2
589	Primary Cutaneous B-Cell Lymphomas. , 2014, , 353-364.		2
590	Phase I/II study of adenovirus-interferon- β (TG1042) in primary cutaneous lymphomas (CL). <i>Journal of Clinical Oncology</i> , 2004, 22, 3039-3039.	0.8	2
591	Phase II double-blind, randomized study of selumetinib (SEL) plus dacarbazine (DTIC) versus placebo (PBO) plus DTIC as first-line treatment for advanced <i>BRAF</i> -mutant cutaneous or unknown primary melanoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9004-9004.	0.8	2
592	The PI3K inhibitor BKM120 has potent antitumor activity in melanoma brain metastases in vitro and in vivo.. <i>Journal of Clinical Oncology</i> , 2013, 31, e20050-e20050.	0.8	2
593	A phase III open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator's choice in advanced melanoma patients progressing post anti-CTLA-4 therapy.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS9105-TPS9105.	0.8	2
594	Patient-reported outcomes (PROs) in KEYNOTE-002, a randomized study of pembrolizumab vs chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) metastatic melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2015, 33, 9040-9040.	0.8	2

#	ARTICLE	IF	CITATIONS
595	Derivation and validation of a prediction scale for response to PD-1 monotherapy.. Journal of Clinical Oncology, 2016, 34, 9514-9514.	0.8	2
596	Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172).. Journal of Clinical Oncology, 2016, 34, 9526-9526.	0.8	2
597	A new B-Raf inhibitor combo for advanced melanoma. Oncotarget, 2018, 9, 34457-34458.	0.8	2
598	Expression of Glioma-associated oncogene homolog 1 as biomarker with sonidegib in advanced basal cell carcinoma. Oncotarget, 2020, 11, 3473-3483.	0.8	2
599	Advances in the drug management of basal cell carcinoma. Expert Opinion on Pharmacotherapy, 2022, 23, 573-582.	0.9	2
600	A primary cutaneous non-T, non-B CD4+, CD56+ lymphoma. Archives of Dermatology, 1996, 132, 550-3.	1.7	2
601	Improved Survival Prediction by Combining Radiological Imaging and S-100B Levels Into a Multivariate Model in Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibition. Frontiers in Oncology, 2022, 12, 830627.	1.3	2
602	What's new in the treatment of melanoma?. Journal of the European Academy of Dermatology and Venereology, 2000, 14, 337-339.	1.3	1
603	Exploring Primary Cutaneous B-Cell Lymphoma by Microarray Technology. Journal of Investigative Dermatology, 2003, 120, vii-viii.	0.3	1
604	Diffuse Cutaneous Melanosis Associated with Malignant Melanoma. Annals of Dermatology, 2015, 27, 780.	0.3	1
605	RESPONSE BY STAGE IN CD30-POSITIVE (CD30+) CUTANEOUS T CELL LYMPHOMA (CTCL) PATIENTS RECEIVING BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN THE PHASE 3 ALCANZA STUDY. Hematological Oncology, 2017, 35, 245-247.	0.8	1
606	Individualized treatment approaches for Langerhans cell histiocytosis. British Journal of Dermatology, 2018, 178, 1423-1424.	1.4	1
607	Reply to E. Hindi and K.R. Hess. Journal of Clinical Oncology, 2019, 37, 1356-1358.	0.8	1
608	Response to: Comment on "Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines". European Journal of Cancer, 2020, 140, 154-157.	1.3	1
609	Recurrent squamous cell carcinoma of the perianal skin: a case report. ESMO Open, 2020, 5, e000786.	2.0	1
610	Tumor-derived GDF-15 to suppress t-lymphocyte recruitment to the tumor microenvironment resulting in resistance to ANTI-PD-1 treatment.. Journal of Clinical Oncology, 2021, 39, e14532-e14532.	0.8	1
611	Collection and preprocessing of fine needle aspirate patient samples for single cell profiling and data analysis. STAR Protocols, 2021, 2, 100581.	0.5	1
612	Immunomodulators in the treatment of cutaneous lymphoma. , 1999, 13, 83.		1

#	ARTICLE	IF	CITATIONS
631	Adjuvant dabrafenib plus trametinib (D + T) versus placebo in patients with resected stage III <i>BRAF</i>^{V600}-mutant melanoma: Updated 5-year distant metastases-free survival (DMFS) analysis of COMBI-AD.. Journal of Clinical Oncology, 2022, 40, 9563-9563.	0.8	1
632	Kutane maligne Lymphome: Update 2006 zu ausgewählten Aspekten. JDDG - Journal of the German Society of Dermatology, 2006, 4, no-no.	0.4	0
633	P001. What's the best therapy for treating resected stage III melanoma patients?. Melanoma Research, 2011, 21, e17.	0.6	0
634	To B-(RAF) or Not to Be. Journal of Investigative Dermatology, 2014, 134, 1200-1201.	0.3	0
635	Histological evaluation of a "residual" metastasis after ipilimumab therapy in a patient with advanced melanoma. Journal of Dermatology, 2015, 42, 927-928.	0.6	0
636	The dynamics of medical care in skin cancers. Current Opinion in Oncology, 2018, 30, 105-106.	1.1	0
637	MLTI-13. RESPONSE ASSESSMENT OF MELANOMA BRAIN METASTASES TREATED BY STEREOTACTIC RADIOTHERAPY OR IMMUNOTHERAPY OR BOTH: A COMPARISON OF RECIST 1.1, RANO AND iRANO CRITERIA. Neuro-Oncology Advances, 2019, 1, i17-i17.	0.4	0
638	Unmasking of a primary desmoplastic melanoma tumour in the course of treatment of a metastatic disease with anti- <i>PD-1</i> monoclonal antibody. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e381-e383.	1.3	0
639	Light-based therapies and scar sarcoidosis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e805-e807.	1.3	0
640	Transient response to nivolumab and relapse after infliximab in a patient with primary cutaneous CD8 ⁺ positive aggressive epidermotropic cytotoxic T _H 1 cell lymphoma. British Journal of Dermatology, 2021, 184, 345-347.	1.4	0
641	Encorafenib plus Binimetinib in patients with locally advanced, unresectable or metastatic BRAF^{V600}-mutant melanoma: First data of the multicenter, multinational, prospective, non-interventional longitudinal study BERING^{MELANOMA}.. Journal of Clinical Oncology, 2021, 39, 9555-9555.	0.8	0
642	Adenovirus-interferon γ (TG1042) demonstrates good tolerance and efficacy in relapsing primary cutaneous lymphoma (PCL): Final results of a phase I/II multicentric trial. Journal of Clinical Oncology, 2006, 24, 7539-7539.	0.8	0
643	Genome Wide Analysis of 41 Mycosis Fungoides Tumor Stage Using Array Comparative Genomic Hybridization Technology.. Blood, 2008, 112, 1769-1769.	0.6	0
644	Melanocytic Tumors. , 2010, , 169-196.		0
645	Cutaneous Lymphoma. , 2010, , 343-354.		0
646	Analysis of KIT expression and mutations in sinonasal, genital, and acrolentiginous melanomas.. Journal of Clinical Oncology, 2012, 30, 8563-8563.	0.8	0
647	Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.. Journal of Clinical Oncology, 2012, 30, 8526-8526.	0.8	0
648	Tumor Staging in Dermatology. , 2015, , 103-118.		0

#	ARTICLE	IF	CITATIONS
649	Real life experience with check point and kinase inhibitors in Swiss advanced melanoma patients.. Journal of Clinical Oncology, 2015, 33, e20064-e20064.	0.8	0
650	The value of ¹⁸ F-fluorodesoxyglucose positron emission tomography (FDG-PET/CT) in the detection of the primary lesion and for staging in brain metastasis (BM) patients with cancer of unknown primary site (CUPS).. Journal of Clinical Oncology, 2017, 35, 2076-2076.	0.8	0
651	BRAF-mutant Melanoma – The COLUMBUS Trial. European Oncology and Haematology, 2018, 14, 78.	0.0	0
652	Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.. Journal of Clinical Oncology, 2018, 36, e18609-e18609.	0.8	0
653	Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study. Blood, 2018, 132, 1646-1646.	0.6	0
654	Targeted Therapies for BRAF-Mutant Metastatic Melanoma. , 2019, , 1-19.		0
655	Dermatological Complications of Systemic Therapies for Melanoma. , 2019, , 1-22.		0
656	Sustainable responses in metastatic melanoma patients with/without brain metastases after immunotherapy induced CR.. Journal of Clinical Oncology, 2019, 37, e21042-e21042.	0.8	0
657	Dermatological Complications of Systemic Therapies for Melanoma. , 2020, , 1337-1358.		0
658	Targeted Therapies for BRAF-Mutant Metastatic Melanoma. , 2020, , 1067-1085.		0
659	Iatrogenic tattoos after acupuncture: successful outcome after treatment with QS Ruby Laser: A case report and review of literature. Laser Therapy, 2019, 28, 139-144.	0.8	0
660	568 – Tumor-derived GDF-15 prevents therapy success of checkpoint inhibitors by blocking T-lymphocyte recruitment. , 2021, 9, A597-A597.		0
661	426 – MK-3475-U02: Phase 1/2 study of investigational agents with or without pembrolizumab versus pembrolizumab monotherapy in melanoma. , 2020, , .		0
662	Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAF ^{V600} -mutant melanoma: Updated data from the multicenter, multinational, prospective, non-interventional longitudinal study BERING ^{MELANOMA} .. Journal of Clinical Oncology, 2022, 40, 9526-9526.	0.8	0